Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,411 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Running Clear all
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

NCT01333137
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Carboplatin, P276-00 along with Gemcitabine and carboplatin
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Burbank, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Not applicable Interventional

Post-Intensive Care Transitional Care, Rehabilitation, and Family-Support

NCT06501365
View directory record Official record
Conditions
Intensive Care Unit Syndrome, Disabilities Multiple, Critical Illness, Caregiver Burden
Interventions
Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS), Enhanced Usual Care Control
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Not applicable Interventional

High Level Mobility Training in Ambulatory Patients With Acquired Non-progressive Central Neurological Injury

NCT04063228
View directory record Official record
Conditions
Neurological Injury
Interventions
Simple Skill Group, Complex Skill Group
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

NCT01505166
View directory record Official record
Conditions
Colon Cancer
Interventions
Vigil™ Vaccine, Placebo
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Vabametkib, Lazertinib
Drug
Lead sponsor
Abion Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

NCT07277582
View directory record Official record
Conditions
Long QT Syndrome (LQTS) 2
Interventions
baseline lead-in, THRV-1268
Other · Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated No phase listed Observational

Influence of Contrast Injection Force on the Accuracy of Vessel Measurements in Cerebral Angiography

NCT03949023
View directory record Official record
Conditions
Cerebral Angiogram
Interventions
Standard of Care Cerebral Angiogram Group
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Spinal Cord Injury Leg Rehabilitation

NCT01498991
View directory record Official record
Conditions
Spinal Cord Injury, Paraplegia, Quadriplegia, Tetraplegia
Interventions
AMES Treatment
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting No phase listed Observational

Exercise Response in Humans With Obesity

NCT05857150
View directory record Official record
Conditions
Obese
Interventions
Treadmill Test, Strength Test, Dual-Energy X-Ray Absorptiometry, Muscle Biopsy, Fat Biopsy, Resting Energy Expenditure, Magnetic resonance imaging
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Not applicable Interventional

Retraining Reaching in Cerebellar Ataxia

NCT03879018
View directory record Official record
Conditions
Cerebellar Ataxia
Interventions
Reach training with visual feedback
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
22 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Acute Exercise on Brain Insulin Sensitivity

NCT05853913
View directory record Official record
Conditions
Aging, Obesity, Insulin Resistance, Cognition, Cardiovascular Disease Risk
Interventions
Exercise
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

Four Way Crossover Closed Loop With Exercise Detection

NCT02862730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934
View directory record Official record
Conditions
Advanced Solid Tumor and Lymphoma Malignancies
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Sarasota, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Aevidum Curriculum and Club

NCT05018689
View directory record Official record
Conditions
Mental Health Wellness 1
Interventions
Aevidum curriculum, Club
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
13 Years to 21 Years
Enrollment
2,557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

COVID-19 Vaccination Take-Up

NCT04867174
View directory record Official record
Conditions
Covid19, Vaccination
Interventions
Financial incentives, Convenient scheduling link, Race concordant, Gender concordant
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Burn Micronutrient Repletion Pilot Study

NCT00879723
View directory record Official record
Conditions
Burn
Interventions
Vitamin and Mineral supplementation
Dietary Supplement
Lead sponsor
Southern Illinois University
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Not applicable Interventional

Steps Towards Osteoarthritis Prevention

NCT06193343
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Adaptive Daily Step Promotion
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
16 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

NCT05355974
View directory record Official record
Conditions
Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
Interventions
Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 17, 2026, 10:20 PM EDT